RxDoctor Payments Data

William Zigrang

Endocrinology, Diabetes & Metabolism · Burlingame, CANPI 1821002783

Payments from drug & device makers

$11,945in general payments, 2019–2025

Across 140 payments — averaging $85.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$8K
  • Amgen$618
  • Novo Nordisk$513
  • Sanofi-aventis U.S. LLC$353
  • Boehringer Ingelheim$346
  • AstraZeneca$275
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$7,60064%
  • Food & beverage$4,31836%
  • Education$280%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,945 in reported general payments places this provider in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$4,495
Metformin Hcl ErMetformin Hcl13$79

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →